Vadodara News Flash

Global Non-Invasive Prenatal Testing (NIPT) market size to reach US$ 8.3 Bn by 2025 at a CAGR of 13.5%

 Breaking News
  • No posts were found

Global Non-Invasive Prenatal Testing (NIPT) market size to reach US$ 8.3 Bn by 2025 at a CAGR of 13.5%

April 12
18:34 2021
Global Non-Invasive Prenatal Testing (NIPT) market size to reach US$ 8.3 Bn by 2025 at a CAGR of 13.5%
The “Global Non-Invasive Prenatal Testing (NIPT) market” report has been added to Reportocean.com’s offering.

Non-Invasive Prenatal Testing (NIPT) is booming on account of the high risk of chromosomal abnormalities with increasing maternal age and the development of advanced non-invasive parenteral testing products. With the increasing prevalence of diseases across the globe, people are opting for products that assist them to stay fit and are investing more in healthcare services. Non-invasive prenatal testing (NIPT) is a screening test that analyzes the genetic information covered in this DNA to screen for a number of defects and provides assurance to expectant parents with accurate genetic information about their baby. It includes advanced bioinformatics technology that evaluates fetal DNA (of placental origin) in maternal blood. The Global Non-Invasive Prenatal Testing (NIPT) Market is estimated to see healthy growth, pegged at a CAGR of around 13.5% throughout the forecast period (2020-2025).

GET SAMPLE PAGES @ https://www.reportocean.com/industry-verticals/sample-request?report_id=bis151259

This test indicates the risk that the fetus will be born with specific genetic abnormalities. Moreover, it analyzes small fragments of DNA that are circulating in a pregnant woman’s blood. Generally, the DNA found inside a cell’s nucleus is free-floating and not within cells, and so is called cell-free DNA (cfDNA) as these fragments contain fewer than 200 DNA building blocks (base pairs) and arise when cells die off. Thus get broken down, and their contents, including DNA, are released into the bloodstream. Non-invasive prenatal testing (NIPT) analyzes chromosomal disorders caused by the presence of an extra or missing copy of a chromosome. The accuracy of the test will not be the same; it varies by disease. Down syndrome is a chromosomal disorder, includes specific congenital disabilities like learning problems and deformity of facial features. A child with down syndrome may have problems with vision and hearing as well as heart defects. NIPT offers various clinical benefits, including prenatal screening tests, such as maternal serum screening (MSS). The screening of Down syndrome NIPT can be performed as early as in the ninth week of pregnancy, as it holds no risk of miscarriage and is able to detect the presence of Down syndrome (trisomy 21) with high sensitivity (99.9%) and specificity (98%).

The high growth in this market attributes to improved healthcare infrastructure, increasing public healthcare expenditure, a large target patient population, and growing awareness regarding advanced technologies. Furthermore, the advancing maternal age can be a risk of genetic disorders in babies due to improper chromosomal division, thereby increasing the demand for the Non-invasive prenatal testing (NIPT) market. Also, the advancements in the existing tests in improved chemistry, advanced functions, and bioinformatics analysis are boosting the market growth. In addition, improving reimbursement policies for average and low-risk pregnancies is another factor responsible for the growth of the market.

Segmentation Overview of the Global Non-Invasive Prenatal Testing (NIPT) Market

The non-invasive prenatal testing (NIPT) market is segmented into product, method, application, and end-use. These major market segments are further categorized into various sub-segments to study the market in detail.

By Product Outlook (Consumables, Assay Kits & Reagents, Disposables, Instruments, NGS Systems, PCR Instruments, Microarrays, Ultrasound Devices, and Others)

By Application Outlook (Trisomy, Microdeletion Syndrome, and Other Applications)

By Method Outlook (Ultrasound Detection, Biochemical Screening Tests, and Cell-free DNA in Maternal Plasma Tests)

By End-Use Outlook (Diagnostic Laboratories, Hospitals)

Key Players Insights

Illumina, Inc., GE Healthcare, Thermo Fisher Scientific Inc., BGI, Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Laboratory Corporation of America Holdings, Natera, Inc., Yourgene Health, among others, are some key market players included in the research study of the global non-invasive prenatal testing (NIPT) market.

READ FULL REPORT @ https://www.reportocean.com/industry-verticals/sample-request?report_id=bis151259

Media Contact
Company Name: Report Ocean
Contact Person: Nishi Sharma
Email: Send Email
Phone: +91-9997112116
Address:BSI Business Park,H-15, Sector-63, Noida
City: Noida
State: UP, 201301
Country: India
Website: www.reportocean.com

Related Articles